Monday, April 27, 2026 11:59:35 AM
Pancreatic cancer abstract for ASCO
Pooled analysis combines safety and efficacy data from 58 patients across three prospective clinical studies conducted at centers in Canada and Israel
Acceptance of abstract comes in the same year as presentations at the ASCO Gastrointestinal Cancers Symposium and at Digestive Disease Week (DDW), reflecting growing interest within the expert scientific community in Alpha DaRT pancreatic cancer clinical data
https://www.alphatau.com/single-post/alpha-tau-announces-presentation-of-pancreatic-cancer-data-at-upcoming-asco-annual-meeting-showcasi
Pooled analysis combines safety and efficacy data from 58 patients across three prospective clinical studies conducted at centers in Canada and Israel
Acceptance of abstract comes in the same year as presentations at the ASCO Gastrointestinal Cancers Symposium and at Digestive Disease Week (DDW), reflecting growing interest within the expert scientific community in Alpha DaRT pancreatic cancer clinical data
https://www.alphatau.com/single-post/alpha-tau-announces-presentation-of-pancreatic-cancer-data-at-upcoming-asco-annual-meeting-showcasi
Recent DRTS News
- Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/18/2026 08:01:00 PM
- Alpha Tau to Participate in May Investor Conferences • GlobeNewswire Inc. • 05/18/2026 12:30:00 PM
- Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET • GlobeNewswire Inc. • 05/11/2026 11:00:00 AM
- Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma • GlobeNewswire Inc. • 05/08/2026 01:10:00 PM
- Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma • GlobeNewswire Inc. • 05/08/2026 01:00:00 PM
- Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute • GlobeNewswire Inc. • 05/07/2026 01:00:00 PM
- Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab • GlobeNewswire Inc. • 05/05/2026 01:14:32 PM
- Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026 • GlobeNewswire Inc. • 05/04/2026 01:17:21 PM
- Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies • GlobeNewswire Inc. • 04/27/2026 01:01:00 PM
- Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel) • GlobeNewswire Inc. • 04/23/2026 01:02:00 PM
- Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial • GlobeNewswire Inc. • 04/23/2026 01:01:00 PM
- Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026 • GlobeNewswire Inc. • 03/31/2026 01:15:00 PM
- Alpha Tau to Present at Sidoti March Virtual Small Cap Conference • GlobeNewswire Inc. • 03/16/2026 02:02:00 PM
- Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/09/2026 08:02:00 PM
- Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead • GlobeNewswire Inc. • 01/29/2026 02:00:00 PM
- DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event • ACCESS Newswire • 01/23/2026 07:50:00 PM
- Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study • GlobeNewswire Inc. • 01/06/2026 02:00:00 PM
- Throwing Precision Darts: The Company Leading Next Evolution of Cancer Radiation • AllPennyStocks.com • 01/05/2026 05:38:00 PM
- Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) • GlobeNewswire Inc. • 01/05/2026 02:00:00 PM
- Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference • GlobeNewswire Inc. • 12/18/2025 02:00:00 PM
- Sidoti Events, LLC's Year-End Virtual Investor Conference • ACCESS Newswire • 12/09/2025 05:48:00 PM
- Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University • GlobeNewswire Inc. • 12/09/2025 02:00:00 PM
- Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium • GlobeNewswire Inc. • 12/04/2025 02:00:00 PM
- Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer • GlobeNewswire Inc. • 12/02/2025 02:00:00 PM
- Alpha Tau to Participate in December Investor Conferences • GlobeNewswire Inc. • 12/01/2025 02:00:00 PM
